Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FDY 5301

Next Previous
Drug Profile

FDY 5301

Alternative Names: FDY-5301

Latest Information Update: 31 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Faraday Pharmaceuticals
  • Class Cardiovascular therapies; Reducing agents
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Myocardial infarction
  • Phase II Musculoskeletal disorders; Sarcopenia
  • No development reported Reperfusion injury

Most Recent Events

  • 10 Jun 2025 Faraday Pharmaceuticals completes the phase III IOCYTE AMI-3 trial in Myocardial infarction in Spain, Hungary, Canada, Poland, Italy, Netherlands, Czech Republic, Slovakia, Portugal, Israel, USA (IV, Injection) (NCT04837001) (EudraCT2021-001924-16)
  • 11 Jun 2024 Faraday Pharmaceuticals completes enrollment in the Phase-III IOCYTE AMI-3 trial in Myocardial infarction in Spain, Hungary, Canada, Poland, Italy, Netherlands, Czechia, Slovakia, Portugal, Israel and the US (IV, Injection) (NCT04837001) (EudraCT2021-001924-16)
  • 04 Jan 2024 European Patent Office notice allows for expansion of FDY 5301 patent protection into the EU

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top